PreveCeutical Medical Completes Third Non-Brokered Private Placement Tranche, Raises $200,000

Completion of Third Tranche and Overall Capital Raised

On July 27, 2026, PreveCeutical announced the successful closing of the third tranche of its non-brokered private placement. This tranche involved issuing 8,000,000 units at $0.025 each, resulting in $200,000 in gross proceeds.

Including the initial tranche closed on May 12, 2026, which raised $340,000 from 13,600,000 units, and the second tranche closed on June 12, 2026, which generated $245,000 from 9,800,000 units, the company has now raised a total of $785,000. Management indicated plans to close additional tranches within the next four weeks to complete the offering.

Unit Structure and Warrant Details

Each unit consists of one common share of PreveCeutical and one-half of a share purchase warrant. Warrants grant holders the option to purchase one additional common share at $0.05 per share within two years from the closing date of the second tranche.

The warrants include an acceleration clause allowing the company to shorten the expiry period if the daily closing price of PreveCeutical shares reaches or exceeds $0.10 on the Canadian Securities Exchange (or another recognized exchange) for at least ten consecutive trading days. Upon acceleration, unexercised warrants expire 30 days after the company issues a news release. This provision encourages warrant holders to exercise their warrants when share price targets are met.

Advisory Fees and Finder Warrants

For the third tranche closing, PreveCeutical paid an advisory commission of $19,600 to an eligible finder and issued 784,000 advisory commission warrants as part of the compensation package.

These advisory commission warrants are exercisable for one common share each at $0.05 per share, with a two-year exercise period starting from the second tranche closing date. They are also subject to the same acceleration rights as the standard offering warrants. This warrant-based compensation helps the company conserve cash while incentivizing finder participation.

Allocation of Third Tranche Proceeds

Proceeds from the third tranche will be allocated toward settling outstanding payables, covering operating expenses, and supporting general working capital. While the company did not provide a detailed breakdown, this allocation aligns with typical working capital management for early-stage life sciences firms.

The focus on payables and operating expenses suggests PreveCeutical is managing near-term cash flow while progressing its research and development programs.

Hold Period and Regulatory Compliance

All securities issued in the third tranche are subject to a four-month hold period plus one day, in line with Canadian securities regulations. This restriction prevents immediate resale by investors and is standard for private placements under exempt offering rules.

The securities have not been registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption. This limitation is common for Canadian companies conducting cross-border private placements.

PreveCeutical's R&D Pipeline Overview

PreveCeutical positions itself as a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products. Its goal is to become a leader in preventive health sciences through robust research and development.

The company’s portfolio includes five main research programs: dual gene therapy targeting diabetes and obesity; the Sol-gel Program; Nature Identical152; peptides for treating various conditions; nonaddictive analgesic peptides as alternatives to opioids like morphine, fentanyl, and oxycodone; and a therapeutic product for athletes with concussions and mild traumatic brain injury. This diverse pipeline reflects multiple therapeutic approaches across different diseases and patient groups.

Future Tranche Plans and Timeline

PreveCeutical plans to complete additional private placement tranches over the next four weeks. Having closed three tranches between mid-May and late July 2026, the company appears to be following a schedule of roughly one tranche every four to six weeks.

Investors will likely monitor announcements of subsequent tranches as continued investor interest at current pricing could indicate confidence in the company’s strategy. Management expects to finalize the entire offering within this defined timeframe.

Stock Listings and Trading Information

PreveCeutical trades on the Canadian Securities Exchange under ticker PREV, on the OTCQB in the U.S. as PRVCF, and on the Frankfurt Stock Exchange under 18H0. Multiple listings provide investors with various trading options, though liquidity may differ across these markets.

The warrant acceleration clause references the Canadian Securities Exchange as the primary trading venue but acknowledges applicability to other recognized exchanges where the shares may trade, reflecting the company’s cross-listing status.

Forward-Looking Statements and Risk Considerations

The announcement contains forward-looking statements about the use of proceeds and the closing of future tranches. These statements are subject to risks and uncertainties that could cause actual outcomes to differ materially.

Risks include potential deviations in the use of funds and the possibility that subsequent tranches may not close as planned. Additional risk factors are detailed in PreveCeutical’s public filings available on SEDAR+ at www.sedarplus.ca. Investors should review these documents to fully understand the risks associated with the company.